Havrix monodose supply constraint
Due to manufacturing issues, UK availability of monovalent hepatitis A vaccine (Havrix Monodose) from GlaxoSmithKline (GSK) will be reduced during 2015. GSK will prioritise the remaining stock for GPs, hospitals, travel clinics and occupational health practitioners. Alternative hepatitis A vaccines are available from other manufacturers and combination hepatitis A vaccines remain available from GSK. Normal supply is expected to resume by early 2016. Further information on 0800 221441.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067168
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com